BAKER BROS. ADVISORS LP Q3 2016 Filing
Filed November 14, 2016
Portfolio Value
$11.0T
Holdings
134
Report Date
Q3 2016
Filing Type
13F-HR
All Holdings (134 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | —Ophthotech Corporation | 35,649 | $1.6B | 0.01% | |
| 102 | —MyoKardia, Inc. | 100,000 | $1.6B | 0.01% | |
| 103 | MCRB1EURSeres Therapeutics, Inc. | 125,000 | $1.5B | 0.01% | |
| 104 | —Palatin Technologies, Inc. | 2,050,000 | $1.3B | 0.01% | |
| 105 | CLLSCellectis S.A. | 50,000 | $1.2B | 0.01% | |
| 106 | —CoLucid Pharmaceuticals, Inc. | 30,310 | $1.2B | 0.01% | |
| 107 | FLGTFulgent Genetics, Inc. | 125,000 | $1.2B | 0.01% | |
| 108 | —Immune Design Corp. | 148,937 | $1.1B | 0.01% | |
| 109 | —Affimed N.V. | 400,000 | $1.1B | 0.01% | |
| 110 | ALDXAldeyra Therapeutics, Inc. | 142,000 | $1.1B | 0.01% | |
| 111 | XLRNAcceleron Pharma Inc. | 28,765 | $1.0B | 0.01% | |
| 112 | —Five Prime Therapeutics, Inc. | 19,247 | $1.0B | 0.01% | |
| 113 | —Tenax Therapeutics, Inc. | 420,000 | $972.0M | 0.01% | |
| 114 | —Mast Therapeutics, Inc. | 8,584,051 | $944.0M | 0.01% | |
| 115 | —Aptose Biosciences Inc. | 404,211 | $909.0M | 0.01% | |
| 116 | INFIQInfinity Pharmaceuticals, Inc. | 580,400 | $905.0M | 0.01% | |
| 117 | DVAXDynavax Technologies Corporation | 75,000 | $787.0M | 0.01% | |
| 118 | ALNYAlnylam Pharmaceuticals, Inc. | 11,340 | $769.0M | 0.01% | |
| 119 | MDGLMadrigal Pharmaceuticals, Inc. | 57,762 | $732.0M | 0.01% | |
| 120 | ADAPYAdaptimmune Therapeutics plc | 100,000 | $705.0M | 0.01% | |
| 121 | —Ritter Pharmaceuticals, Inc. | 400,000 | $672.0M | 0.01% | |
| 122 | —Windtree Therapeutics, Inc. | 254,973 | $653.0M | 0.01% | |
| 123 | CMRXEURChimerix, Inc. | 115,216 | $638.0M | 0.01% | |
| 124 | I9DNArbutus Biopharma Corporation | 180,582 | $621.0M | 0.01% | |
| 125 | —Abeona Therapeutics Inc. | 101,680 | $610.0M | 0.01% | |
| 126 | —BioDelivery Sciences International, Inc. | 210,021 | $567.0M | 0.01% | |
| 127 | —Foundation Medicine, Inc. | 20,892 | $488.0M | 0.00% | |
| 128 | —Achaogen, Inc. | 100,000 | $479.0M | 0.00% | |
| 129 | —CytRx Corporation | 659,995 | $388.0M | 0.00% | |
| 130 | —ProNAi Therapeutics, Inc. | 200,000 | $364.0M | 0.00% | |
| 131 | —La Jolla Pharmaceutical Company | 13,746 | $327.0M | 0.00% | |
| 132 | CCXIEURChemoCentryx, Inc. | 49,064 | $296.0M | 0.00% | |
| 133 | BGMS 6 PERPCyclacel Pharmaceuticals, Inc. | 13,253 | $90.0M | 0.00% | |
| 134 | —BioTime, Inc. | 20,084 | $17.0M | 0.00% |
PreviousPage 2 of 2